Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 12,734 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Male Clear all
Recruiting Early Phase 1 Interventional

Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation

NCT07308808
View directory record Official record
Conditions
Spinal Cord Injuries (SCI), Neurogenic Bladder, Urinary Tract Infection (Diagnosis)
Interventions
Lactobacillus Crispatus, Saline bladder wash
Drug · Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 4 Interventional

Local Anesthesia for Prostate Biopsy

NCT00422708
View directory record Official record
Conditions
Prostate Cancer
Interventions
Local anesthesia
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Contrast-enhanced Ultrasound of the Kidney

NCT02684435
View directory record Official record
Conditions
Chronic Kidney Disease, Cystic Kidney Disease
Interventions
Perflutren lipid microsphere
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking

NCT01535040
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Tobacco Use Disorder
Interventions
memantine hydrochloride, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer

NCT03015740
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration, Sitravatinib
Other · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Not applicable Interventional

Does Detailed Informed Consent for Cardiopulmonary Resuscitation and Mechanical Ventilation Impact Patients' Decisions and Outcomes?

NCT01878968
View directory record Official record
Conditions
Congestive Heart Failure, Infections, Sepsis, Acute Renal Failure, Stroke
Interventions
Script and CPR/Mechanical ventilation video.
Other
Lead sponsor
Jewish Hospital, Cincinnati, Ohio
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Oct 21, 2026, 5:22 PM EDT
Not listed Not applicable Interventional

The Use of cineMRI to Evaluate Botox in Patients With Medication Refractory Overactive Bladder

NCT02315950
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botulinum toxin and cineMRI-UDS
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 21, 2026, 5:22 PM EDT
Enrolling by invitation No phase listed Observational

Idiopathic Diseases of Man

NCT01440218
View directory record Official record
Conditions
Rare Disease, Idiopathic Disease
Interventions
Not listed
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2030
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 2 Interventional

Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors

NCT00003518
View directory record Official record
Conditions
Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
15 Years to 120 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
18
States / cities
Denver, Colorado • Chicago, Illinois • Urbana, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer

NCT00939510
View directory record Official record
Conditions
Prostate Cancer
Interventions
sargramostim, lenalidomide, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Robert Dreicer MD
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

NCT03338790
View directory record Official record
Conditions
Prostate Cancer
Interventions
nivolumab, docetaxel, enzalutamide, rucaparib, prednisone
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
19
States / cities
Daphne, Alabama • Rancho Mirage, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Terminated Not applicable Interventional Results available

Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma

NCT02138578
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
SBRT, RFA
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Not applicable Interventional Results available

Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial

NCT01157676
View directory record Official record
Conditions
Bladder Cancer Requiring Cystectomy
Interventions
Open radical cystectomy, Robotic assisted radical cystectomy, DaVinci robot
Procedure · Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
16
States / cities
Phoenix, Arizona • Orange, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Not applicable Interventional Results available

Empowering Patients On Choices for Renal Replacement Therapy (Aim 3) (EPOCH-RRT)

NCT02488317
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Decision Aid
Other
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 21, 2026, 5:22 PM EDT
Recruiting Not applicable Interventional

Efficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic Pain

NCT05868668
View directory record Official record
Conditions
Erectile Dysfunction Due to Arterial Insufficiency, Erectile Dysfunction, Erectile Dysfunction Due to Arterial Disease, Chronic Pelvic Pain Syndrome, Chronic Prostatitis, Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction Following Radiation Therapy
Interventions
Focused shockwave, Radial wave, Sham treatment
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years and older · Male only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Terminated Phase 1 Interventional

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

NCT05999968
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Abemaciclib, Darolutamide, LHRH agonist/antagonist
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Springdale, Arkansas • Mineola, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

NCT01615120
View directory record Official record
Conditions
Prostate Cancer
Interventions
GTx-758 125 mg, GTx-758 250 mg
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
26
States / cities
Burbank, California • Los Angeles, California • San Bernardino, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 21, 2026, 5:22 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of Efficacy and Safety of Votiva for Vaginal Rejuvenation

NCT03520426
View directory record Official record
Conditions
Vaginal Atrophy, Vaginal Relaxation, Stress Urinary Incontinence
Interventions
Votiva RF
Device
Lead sponsor
Walden, Jennifer L., M.D.,P.L.L.C.
Individual
Eligibility
25 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
New York, New York • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 21, 2026, 5:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Does Hip Strength Impact Active Females Rate of Pelvic Floor Dysfunction? The Primary Goal of This Research is to Collect Data on Hip Strength for Active Females and Assess if There is a Relationship Between Hip Strength and Pelvic Floor Dysfunction (PFD).

NCT07119476
View directory record Official record
Conditions
Pelvic Floor Muscle Weakness, Pelvic Floor Disorder, Pelvic Pain, Hip Strength
Interventions
Not listed
Lead sponsor
George Fox University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Newberg, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

NCT01809691
View directory record Official record
Conditions
Prostate Cancer
Interventions
TAK-700, Bicalutamide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
1,313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
560
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 374 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

NCT00036933
View directory record Official record
Conditions
Prostate Cancer
Interventions
MUC-2-Globo H-KLH conjugate vaccine, QS21
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen

NCT00715078
View directory record Official record
Conditions
Prostate Cancer
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
12
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 21, 2026, 5:22 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers

NCT01044108
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC 0070-0002-0453, '2-0453, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 21, 2026, 5:22 PM EDT
Withdrawn Phase 4 Interventional

Caudal vs. Pudendal Block in Peds GU

NCT05708989
View directory record Official record
Conditions
Hypospadias, Penile Torsion, Chordee, Phimosis
Interventions
Caudal Block, Ultrasound-guided Pudendal Block, Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine, Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine.
Procedure · Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
6 Months to 3 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 21, 2026, 5:22 PM EDT